

1 **The lower-airway microbiome and metabolome in preterm infants: Identifying**
2 **potential predictive biomarkers of bronchopulmonary dysplasia**

3 **Qi Xu², Jialin Yu^{1*}, Junli He^{1, 3}, Yu He³,**

4 ¹Department of Neonatology, Shenzhen University General Hospital, Shenzhen,
5 China

6 ²Children's Hospital, Capital Institute of Pediatrics, Beijing, China

7 ³Department of Neonatology, Children's Hospital of Chongqing Medical University,
8 Chongqing, China

9

10 Correspondence: Jialin Yu

11 Email address: yujialin486@126.com

12 Post address: No. 1098, Xueyuan Avenue, Xili University Town, Shenzhen, China

13

14 **Abstract**

15 The lower-airway microbiome may influence the pathogenesis of lung disease.
16 Bronchopulmonary dysplasia (BPD) is a serious morbidity associated with preterm
17 birth that may be influenced by lower-airway microbial or metabolic alterations. This
18 study used 16S rRNA gene sequencing, metabolomic analyses, and the Kyoto
19 Encyclopedia of Genes and Genomes (KEGG) database to investigate the
20 lower-airway microbiome and metabolome in a cohort of preterm infants with mild,
21 moderate, or severe BPD or no BPD. Differences in the diversity and composition of
22 the infants' lower airway microbiota, as well as metabolic status, were initially
23 observed, but became less pronounced at 7 days of life. Decreased diversity of the
24 lower-airway microbiome, increased abundance of *Stenotrophomonas*, and increased
25 level of sn-glycerol 3-phosphoethanolamine were associated with increased BPD
26 severity, and have potential as predictive biomarkers for BPD. *Stenotrophomonas* may
27 contribute to the development of BPD and influence the composition of the
28 lower-airway microbiome through its metabolite, sn-glycerol 3-phosphoethanolamine.
29 These findings provide novel insights into the lower-airway microbiome and its role
30 in BPD.

31 **The lower-airway microbiome and metabolome in preterm infants: Identifying**
32 **potential predictive biomarkers of bronchopulmonary dysplasia**

33 **Qi Xu², Jialin Yu^{1*}, Junli He¹, Qi Tan³, Yu He³,**

34 ¹Department of Neonatology, Shenzhen University General Hospital, Shenzhen,
35 China

36 ²Children's Hospital, Capital Institute of Pediatrics, Beijing

37 ³Department of Neonatology, Children's Hospital of Chongqing Medical University,
38 Chongqing, China

39

40 **Abstract**

41 The lower-airway microbiome may influence the pathogenesis of lung disease.
42 Bronchopulmonary dysplasia (BPD) is a serious morbidity associated with preterm
43 birth that may be influenced by lower-airway microbial or metabolic alterations. This
44 study used 16S rRNA gene sequencing, metabolomic analyses, and the Kyoto
45 Encyclopedia of Genes and Genomes (KEGG) database to investigate the
46 lower-airway microbiome and metabolome in a cohort of preterm infants with mild,
47 moderate, or severe BPD or no BPD. Differences in the diversity and composition of
48 the infants' lower airway microbiota, as well as metabolic status, were initially
49 observed, but became less pronounced at 7 days of life. Decreased diversity of the
50 lower-airway microbiome, increased abundance of *Stenotrophomonas*, and increased
51 level of sn-glycerol 3-phosphoethanolamine were associated with increased BPD
52 severity, and have potential as predictive biomarkers for BPD. *Stenotrophomonas* may
53 contribute to the development of BPD and influence the composition of the
54 lower-airway microbiome through its metabolite, sn-glycerol 3-phosphoethanolamine.
55 These findings provide novel insights into the lower-airway microbiome and its role
56 in BPD.

57 **Key words:** BPD, microbiome, genomics, metabonomic

58

59

60

61 **1. Introduction**

62 Bronchopulmonary dysplasia (BPD) is a serious morbidity associated with
63 preterm birth that affects an estimated 50% of infants born at < 28 weeks of gestation
64 [1]. Infants with BPD have an increased risk of mortality during the first year. Those
65 who survive may suffer long-term pulmonary impairment and abnormal
66 neurodevelopment, which can result in substantial healthcare resource utilization and
67 cost [2]. Risk factors for BPD include, but are not limited to, gestational age at birth,
68 impaired growth for gestational age, low infant birth weight, infectious exposures,
69 barotrauma, oxygen exposure, and environmental cigarette smoke [3].

70 Evidence from epidemiological data, clinical data, and animal models indicate a
71 key role for the microbiome in lung disease [4-6], and indicate that the lower-airway
72 microbiome is altered in multiple respiratory disorders [7, 8]. Some reports show that
73 the lower-airway microbiome is present at birth, and microbial dysbiosis may be
74 associated with BPD [9, 10]. However, by now the related research is rare and the
75 present results differ from each other, so it needs further research. What's more, the
76 mechanisms by which the microbiome alterations lead to BPD have never been
77 addressed. Gut microbiota is associated with a variety of human diseases through
78 metabolites [11]. We hypothesized that lower-airway microbial metabolism plays a
79 role in the pathogenesis of BPD.

80 In this prospective observational cohort study, tracheal aspirates (TA) were
81 collected during mechanical ventilation of infants to investigate 1) the lower-airway
82 microbiome at birth (Day 1) and on Day 7 after birth; 2) the lower-airway
83 metabolomic signatures at birth and on Day 7 after birth; and 3) the relationship
84 between differential metabolites and specific bacteria among infants with severe BPD,
85 moderate BPD, mild BPD, and no BPD.

86

87 **2. Methods**

88 This prospective observational cohort study was conducted at the Neonatal
89 Intensive Care Unit of the Children's Hospital of Chongqing Medical University
90 between October 2017 and July 2018. The Institutional Review Board of Chongqing

91 Medical University approved the protocol. Informed consent was received from the
92 parents or guardians of all participants. The study was performed in accordance with
93 approved guidelines.

94 **2.1 Patient population and clinical data collection**

95 Infants born at <34 weeks gestation that underwent endotracheal intubation and
96 mechanical ventilation in the first 24 h of life and remained intubated until at least
97 Day 7 after birth were included in this study. Exclusion criteria were: 1) clinical
98 evidence of congenital heart disease (except patent ductus arteriosus [PDA], patent
99 foramen ovale [PFO] or atrial septal defect [ASD] < 1cm, or ventricular septal defect
100 [VSD] < 2mm if known prior to enrollment); 2) lethal congenital abnormality; 3)
101 congenital sepsis; 4) evidence of pulmonary hypoplasia; or 5) futile cases (anticipated
102 death prior to hospital discharge) [10].

103 Infants were divided into four groups stratified by the diagnosis and severity of
104 BPD: severe BPD, moderate BPD, mild BPD, and no BPD. BPD was diagnosed
105 based on the need for supplemental oxygen at 28 days of age [12, 13]. BPD status and
106 severity was assessed at 36 weeks postmenstrual age according to the National
107 Institutes of Health workshop definition [13]. Late onset sepsis was defined as a
108 positive blood culture after 72 h of life.

109 Clinical data were collected from a review of electronic medical records at study
110 enrollment and during hospitalization. Information on maternal history, delivery, and
111 clinical assessments was recorded.

112 **2.2 Sample collection**

113 Tracheal aspirates (TA) were collected during mechanical ventilation at birth
114 (Day 1) and on Day 7 after birth according to a previously published protocol [13-15].
115 Briefly, 0.5 ml of sterile isotonic saline was instilled into the infants' endotracheal
116 tubes. Infants were manually ventilated through their endotracheal tube for three
117 breaths using a bag-mask, and fluid was suctioned into a sterile mucus trap [14].
118 Samples were divided into 2 aliquots for extraction of bacterial DNA or metabolomics
119 research and frozen at -80°C until further processing.

120 **2.3 Isolation of microbial DNA, creation of 16S V4 amplicon library, and DNA**
121 **sequencing**

122 Microbial genomic DNA from each sample was isolated and purified. The V4
123 region of the 16S rRNA gene from the microbial DNA was amplified using a
124 polymerase chain reaction (PCR) with unique bar coded primers to create an
125 “amplicon library” [16]. The library was sequenced using the Illumina MiSeq
126 platform and subsequently quantified (KAPA Library Quantification Kit KK4824),
127 according to the manufacturer's instructions.

128 **2.4 Profiling of 16S rRNA gene sequencing data**

129 Raw sequences were processed with the Quantitative Insights into Microbial
130 Ecology (QIIME) 1.8.0 pipeline¹. The concat function was used to combine reads into
131 tags according to an overlapping relationship. Reads from each sample were separated
132 with barcodes, and low quality reads were removed. Processed tags were clustered at
133 97% similarity into operational taxonomic units (OTUs). Taxonomy was assigned to
134 OTUs by matching to the Greengenes database (Release 13.8)². Alpha diversity
135 analyses (Shannon index) and beta diversity analyses (principal coordinate analysis
136 [PCoA]) were performed.

137 **2.4 Metabolomics analysis based on UHPLC-Q-TOF/MS**

138 TA samples were analyzed using an ultra-high-performance liquid
139 chromatography (UHPLC) system (1290 Infinity LC, Agilent Technologies) coupled
140 to a quadrupole time-of-flight mass spectrometer (AB Sciex TripleTOF 6600) at
141 Shanghai Applied Protein Technology Co., Ltd.

142 Samples were thawed at 4°C and 100 µL aliquots were mixed with 400 µL of
143 cold methanol/acetonitrile (1:1, v/v) to remove the protein. After centrifuging for 15
144 min (14000g, 4 °C), the supernatant was dried in a vacuum centrifuge. For liquid
145 chromatography-mass spectrometry (LC-MS), samples were dissolved in 100 µL
146 acetonitrile/water (1:1, v/v). Pooled quality control (QC) samples were used to
147 monitor the stability and repeatability of instrument analysis. The QC samples were
148 inserted regularly and analyzed in every 5 samples.

149 Raw LS electrospray ionization (ESI) MS data were converted into m/z format

150 and analyzed for non-linear retention time (RT) alignment, peak detection, and
151 filtration.

152 **2.5 Profiling of metabolomics data**

153 Processed data were normalized to total peak intensity, imported into SIMCA-P
154 (version 14.1, Umetrics, Umea, Sweden), and analyzed using Pareto-scaled principal
155 component analysis (PCA) and orthogonal partial least-squares discriminant analysis
156 (OPLS-DA). The variable importance in the projection (VIP) value for each variable
157 in the OPLS-DA model was calculated to indicate its contribution to the classification.
158 One-way ANOVA was used to determine the significance of each metabolite with a
159 VIP value >1 . $P < 0.05$ were considered statistically significant. Discriminatory
160 metabolites within the data set were visualized as heat maps, which were generated
161 using a hierarchical clustering algorithm. Molecules associated with significant
162 changes were searched against the Kyoto Encyclopedia of Genes and Genomes
163 (KEGG) database (<http://www.genome.jp/kegg/pathway.html>).

164 **2.6 Statistical analysis**

165 Statistical analysis was performed using SPSS version 22.0 for Windows (SPSS
166 Inc., USA). Normally distributed data are expressed as mean \pm SD; non-normally
167 distributed data are expressed as median and interquartile range (IQR). Between
168 group differences were analyzed with Fisher's Exact test for categorical variables and
169 Kruskal-Wallis test for continuous variables after subsampling. Pairwise comparison
170 was performed with White's non-parametric t-test. Correlations between
171 microbiome-related metabolites and bacterial species were evaluated using Pearson's
172 correlation coefficient. $P < 0.05$ was considered statistically significant.

173

174 **3.0 Results**

175 **3.1 Demographic and clinical characteristics of the enrolled patients**

176 This study included 30 premature infants divided into 4 groups, including 10
177 infants with severe BPD, 5 infants with moderate BPD, 10 infants with mild BPD,
178 and 5 infants with no BPD. The demographic and clinical characteristics of the
179 included infants are shown in **Table 1**. There were no significant differences in the

180 demographic and clinical characteristics between the groups, except for number of
181 hours of mechanical ventilation and number of days of antibiotics.

182 **3.2 Diversity and composition of the lower-airway microbiome**

183 The Shannon index was significantly lower at birth (Day 1) ($P=0.0019$; **Figure**
184 **1a**) and on Day 7 after birth ($P=0.016$; **Figure 1b**) in infants with BPD compared to
185 no BPD. The difference was more pronounced on Day 1 and was negatively
186 correlated with the severity of BPD. Principal coordinates analysis (PCoA) showed a
187 significant difference in the bacterial composition of the lower-airway microbiome at
188 birth (Day 1) between the four groups (**Figure 1c**), and a less distinct difference on
189 Day 7 after birth (**Figure 1d**).

190 At the phylum level, *Proteobacteria* was dominant in the lower-airway
191 microbiome of all infants at birth (Day 1) (**Figure 1e**) and on Day 7 after birth
192 (**Figure 1f**), and there were no significant differences in the composition of the
193 lower-airway microbiome between the four groups. At the genus level, the
194 composition of the lower-airway microbiome was significantly different between
195 groups at birth (Day 1). *Stenotrophomonas* was more abundant in infants with BPD
196 compared to no BPD, and abundance was positively correlated with the severity of
197 disease ($P < 0.05$) (**Figure 2a**). Findings on Day 7 after birth were similar, but not
198 statistically significant ($P=0.064$) (**Figure 2b**).

199 **3.3 Metabolomic analysis of tracheal aspirates (TA)**

200 TAs were subjected to LC/MS analysis in positive ion mode (ES+) and negative
201 ion mode (ES-).

202 Principle component analysis (PCA) was performed to reduce dimensionality in
203 the dataset (**Figure 3a, b**). Hierarchical clustering heat maps visualized patterns in
204 molecular data across groups (**Figure 3c-f**). There were significant differences in 63
205 metabolites, including 23 in ES- and 40 in ES+ (Figure 3c,d), between the four
206 groups at birth (Day 1), and 29 metabolites, including 11 in ES- and 18 in ES+, on
207 Day 7 after birth (**Figure 3e-f**). Among these metabolites, sn-glycerol
208 3-phosphoethanolamine was positively correlated with BPD severity at birth (Day 1)
209 (**Figure 4**), but not on Day 7 after birth.

210 **3.4 Correlation between the lower-airway microbiome and metabolites**

211 Pearson's correlation coefficient was used to explore the functional correlation
212 between the changes in the lower-airway microbiome and differences in metabolites
213 across the four groups at birth (Day 1) (**Figure 5**). There was a significant positive
214 correlation between the abundance of *Stenotrophomonas* and sn-glycerol
215 3-phosphoethanolamine levels ($r=0.45$) ($P<0.05$).

216

217 **Discussion**

218 Studies investigating the correlation between BPD and the lower-airway
219 microbiome in infants are scarce, and there remains an unmet clinical need to describe
220 the lower-airway microbial communities and lower-airway metabolomic signatures in
221 patients with BPD. Findings will allow the identification of microbial biomarkers for
222 early detection of BPD and further understanding of the pathophysiology of BPD.

223 The present study used 16S rRNA gene sequencing, metabolomic analyses, and
224 the KEGG database in attempt to fill these evidence gaps. Results showed that
225 multiple bacterial taxa can be identified in the respiratory secretions of intubated
226 premature infants, even at birth and prior to surfactant administration. The diversity
227 and composition of the lower-airway microbiome in infants with and without BPD
228 varied at birth, but the differences became less pronounced on Day 7 of life.
229 Consistent with a previous report, our study showed lower diversity in the
230 lower-airway microbiome of infants that developed BPD [14]. Our results also
231 revealed that alpha diversity of lower-airway communities was negatively correlated
232 with BPD severity. At the phylum level, there were no significant differences in the
233 composition of the lower-airway microbiome in infants with and without BPD or
234 according to BDP severity. *Proteobacteria* was the most abundant microbe in all
235 infants. These data align with one previous report, [14], but differ from another, which
236 found that *Staphylococcus* and *Ureaplasma* were the most dominate lower-airway
237 microbes in infants in their institution [10]. These disparate findings may be due to
238 different environments, which likely influenced the composition of the lower-airway
239 microbiome. At the genus level, *Stenotrophomonas* was significantly more abundant

240 in infants with BPD compared to no BPD, and the abundance of *Stenotrophomonas*
241 was positively correlated with BPD severity. These findings suggest that decreased
242 diversity of the lower-airway microbiome and increased abundance of
243 *Stenotrophomonas* in the lower-airway microbial community of intubated premature
244 infants have potential as microbial biomarkers for early detection of BPD.

245 *Stenotrophomonas* is a nosocomial opportunistic pathogen of the
246 *Xanthomonadaceae* family [17]. *Stenotrophomonas* isolated from the environment or
247 in the clinical setting exhibits resistance to antibiotics and stress and forms biofilms
248 on various surfaces, including the abiotic surfaces of catheters and prosthetic devices
249 [18, 19]. *Stenotrophomonas* colonizes the lungs of patients with cystic fibrosis and
250 those who are immunocompromised, and may represent a marker of chronic lung
251 disease [18, 20-22]. *Stenotrophomonas* can influence the spatial organization and thus
252 the function and composition of complex microbiomes [23, 24]. Data from the present
253 study suggest a role for *Stenotrophomonas* in the pathogenesis of BPD in intubated
254 premature infants.

255 As the composition of the lower-airway microbiome in preterm infants varied
256 with the presence or absence of BPD and with BPD severity, we characterized the
257 lower-airway metabolome in these infants. Findings showed significant differences
258 between infants in 63 metabolites at birth (Day 1) and 29 metabolites on Day 7 of life,
259 implying that metabolite variation paralleled that of the lower-airway microbiome.
260 Among these metabolites, sn-glycerol 3-phosphoethanolamine was
261 positively correlated with BPD severity, identifying it as a potential metabolic
262 biomarker for early detection of BPD. The KEGG database showed that sn-glycerol
263 3-phosphoethanolamine has a role in glycerophospholipid metabolism.
264 Glycerophospholipid has structural functions in bacteria, facilitates bacterial
265 adaptation to environmental conditions, and is involved in bacteria–host interactions
266 [28]. Glycerophospholipid is also associated with the pathophysiology of chronic
267 obstructive pulmonary disease (COPD) [29]. These findings suggest that sn-glycerol
268 3-phosphoethanolamine may affect lower-airway microbiome composition and
269 respiratory health in preterm infants. Our findings also identified a significant positive

270 correlation between the abundance of *Stenotrophomonas* and sn-glycerol
271 3-phosphoethanolamine levels, an association that was confirmed with the KEGG
272 database. This indicates that *Stenotrophomonas* may be abundant in the lower-airway
273 microbiome of infants with BPD and responsible for the production of sn-glycerol
274 3-phosphoethanolamine, which may act as a pathogenic signal in these patients.

275 To the author's knowledge, this prospective study is the first to identify a
276 microbiome-metabolome signature in preterm infants with BPD. However, this study
277 had several limitations. First, the sample size was small. Second, the data did not
278 provide evidence that the lower-airway microbiome directly contributed to BPD.
279 Although it will be challenging to determine a causal relationship between the
280 lower-airway microbiome, metabolites and BPD development, further investigations
281 are warranted.

282 In summary, there were significant differences in the diversity and composition
283 of the lower-airway microbiome and metabolome in preterm infants with severe,
284 moderate, or mild BPD or no BPD; the differences were more pronounced at birth
285 (Day 1) than on Day 7 of life. Decreased diversity of the lower-airway microbiome,
286 increased abundance of *Stenotrophomonas*, and increased level of sn-glycerol
287 3-phosphoethanolamine were positively associated with BPD severity, and have
288 potential as predictive biomarkers for BPD. *Stenotrophomonas* may contribute to the
289 development of BPD and influence the composition of the lower-airway microbiome
290 through its metabolite, sn-glycerol 3-phosphoethanolamine. These findings provide
291 novel insights into the lower-airway microbiome and its functions in BPD.

292

293 **Funding:** National Natural Science Foundation of China Fund Project (No. 81571483,
294 81971431), Shenzhen Science and Technology Innovation Free Exploration Project
295 (JCYJ20170817100735621), Shenzhen Synthetic Biology Innovation Research
296 Institute, Chinese Academy of Sciences, Opening to the Outside World Fund Project
297 (DWKF20190008), Scientific Research Fund of Shenzhen University General
298 Hospital (SUGH2020QD003).

299

300 **Competing interests:** There are no ethical/legal or financial conflicts involved in the
301 article.

302

303 **References:**

- 304 [1] Onland W, Cools F, Kroon A, et al. Effect of Hydrocortisone Therapy Initiated 7 to 14 Days
305 After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants
306 Receiving Mechanical Ventilation: A Randomized Clinical Trial [J]. *JAMA*, 2019, 321(4):
307 354-363.
- 308 [2] Erik A. Jensen MM, Kevin Dysart, MD1, Marie G. Gantz, PhD2, Scott McDonald BS2, Nicolas A.
309 Bamat, MD MSCE1, Martin Keszler, MD3; Haresh Kirpalani, BM MSc1; Matthew M. Laughon,
310 MD MPH4; Brenda B. Poindexter, MD MS5; Andrea F. Duncan, MD MS6; Bradley A. Yoder,
311 MD7; Eric C. Eichenwald, MD1, Sara B. DeMauro, MD MSCE. The Diagnosis of
312 Bronchopulmonary Dysplasia in Very Preterm Infants: An Evidence-Based Approach [J]. *Am J*
313 *Respir Crit Care Med*, 2019, doi: 10.1164/rccm.201812-2348OC(
- 314 [3] Bradley Wallace M, Amelie Peisl, BS,, Gregory Seedorf B, Taylor Nowlin, BS, Christina Kim, MD,
315 Jennifer Bosco, PhD, Jon Kenniston, PhD, Dennis Keefe, PhD, and Steven H. Abman M.
316 Anti-sFlt-1 Therapy Preserves Lung Alveolar and Vascular Growth in Antenatal Models of BPD
317 [J]. *American journal of respiratory and critical care medicine*, 2018, 197(6): 776-787.
- 318 [4] Remot A, Descamps D, Noordine ML, et al. Bacteria isolated from lung modulate asthma
319 susceptibility in mice [J]. *ISME J*, 2017, 11(5): 1061-1074.
- 320 [5] Pammi M, Lal CV, Wagner BD, et al. Airway Microbiome and Development of
321 Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review [J]. *J Pediatr*, 2019,
322 204(126-133 e122.
- 323 [6] Francisco Casado REM. The emergence of preclinical studies on the role of the microbiome in
324 lung development and experimental animal models of bronchopulmonary dysplasia [J]. *Am J*
325 *Physiol Lung Cell Mol Physiol*, 2020,
- 326 [7] Ubags NDJ and Marsland BJ. Mechanistic insight into the function of the microbiome in lung
327 diseases [J]. *Eur Respir J*, 2017, 50(3):
- 328 [8] Tracy M, Cogen J and Hoffman LR. The pediatric microbiome and the lung [J]. *Curr Opin*
329 *Pediatr*, 2015, 27(3): 348-355.
- 330 [9] Lal CV, Travers C, Aghai ZH, et al. The Airway Microbiome at Birth [J]. *Sci Rep*, 2016, 6(31023.
- 331 [10] Wagner BD, Sontag MK, Harris JK, et al. Airway Microbial Community Turnover Differs by BPD
332 Severity in Ventilated Preterm Infants [J]. *PLoS One*, 2017, 12(1): e0170120.
- 333 [11] Vojinovic D, Radjabzadeh D, Kurilshikov A, et al. Relationship between gut microbiota and
334 circulating metabolites in population-based cohorts [J]. *Nat Commun*, 2019, 10(1): 5813.
- 335 [12] Kjellberg M, Bjorkman K, Rohdin M, et al. Bronchopulmonary dysplasia: clinical grading in
336 relation to ventilation/perfusion mismatch measured by single photon emission computed
337 tomography [J]. *Pediatr Pulmonol*, 2013, 48(12): 1206-1213.
- 338 [13] BANCALARI AHJaE. Bronchopulmonary Dysplasia [J]. *American journal of respiratory and*
339 *critical care medicine*, 2001, 163(7): 1723-1729.
- 340 [14] Lohmann P, Luna RA, Hollister EB, et al. The airway microbiome of intubated premature
341 infants: characteristics and changes that predict the development of bronchopulmonary

- 342 dysplasia [J]. *Pediatr Res*, 2014, 76(3): 294-301.
- 343 [15] Mourani PM, Harris JK, Sontag MK, et al. Molecular identification of bacteria in tracheal
344 aspirate fluid from mechanically ventilated preterm infants [J]. *PLoS One*, 2011, 6(10):
345 e25959.
- 346 [16] Lu K, Abo RP, Schlieper KA, et al. Arsenic exposure perturbs the gut microbiome and its
347 metabolic profile in mice: an integrated metagenomics and metabolomics analysis [J].
348 *Environ Health Perspect*, 2014, 122(3): 284-291.
- 349 [17] Ryan RP, Monchy S, Cardinale M, et al. The versatility and adaptation of bacteria from the
350 genus *Stenotrophomonas* [J]. *Nat Rev Microbiol*, 2009, 7(7): 514-525.
- 351 [18] An SQ and Berg G. *Stenotrophomonas maltophilia* [J]. *Trends Microbiol*, 2018, 26(7): 637-638.
- 352 [19] David Skurnik¹; Michael R. Davis¹; JDBKLMCCDRDCTRLWTM-L, Vargas⁵; CCRHTRMELTSO and
353 Alexander J. McAdam⁶; Tami D. Lieberman⁷; Roy Kishony⁷ J J L, 10; Gerald B. Pier; Joanna B.
354 Goldberg²; Gregory P. Priebe^{1,3}. Targeting pan-resistant bacteria with antibodies to a broadly
355 conserved surface polysaccharide expressed during infection [J]. *Journal of Infectious*
356 *Diseases*, 2012, 205(11): 1709-1718.
- 357 [20] Lisa C Crossman VCG, J Maxwell Dow, Georgios S Vernikos, Aki Okazaki, Mohammed Sebahia,
358 David Saunders, Claire Arrowsmith, Tim Carver, Nicholas Peters, Ellen Adlem, Arnaud
359 Kerhornou, Angela Lord, Lee Murphy, Katharine Seeger, Robert Squares, Simon Rutter,
360 Michael A Quail, MariAdele Rajandream, David Harris, Carol Churcher, Stephen D Bentley,
361 Julian Parkhill, Nicholas R Thomson and Matthew B Avison. The complete genome,
362 comparative and functional analysis of *Stenotrophomonas maltophilia* reveals an organism
363 heavily shielded by drug resistance determinants [J]. *Genome Biology*, 2008, 9(4):
364 [21] Reshma Amin VW. Antibiotic treatment for *Stenotrophomonas maltophilia* in people with
365 cystic fibrosis [J]. *TheCochrane Library*, 2012, 5.
- 366 [22] Watson L, Esterly J, Jensen AO, et al. Sulfamethoxazole/trimethoprim versus fluoroquinolones
367 for the treatment of *Stenotrophomonas maltophilia* bloodstream infections [J]. *J Glob*
368 *Antimicrob Resist*, 2018, 12(104-106).
- 369 [23] Liu W, Russel J, Roder HL, et al. Low-abundant species facilitates specific spatial organization
370 that promotes multispecies biofilm formation [J]. *Environ Microbiol*, 2017, 19(7): 2893-2905.
- 371 [24] Liu W, Russel J, Burmolle M, et al. Micro-scale intermixing: a requisite for stable and
372 synergistic co-establishment in a four-species biofilm [J]. *ISME J*, 2018, 12(8): 1940-1951.
- 373 [25] Blutt SE and Estes MK. Gut Bacterial Bouncers: Keeping Viral Pathogens out of the Epithelium
374 [J]. *Cell Host Microbe*, 2019, 26(5): 569-570.
- 375 [26] Olin A, Henckel E, Chen Y, et al. Stereotypic Immune System Development in Newborn
376 Children [J]. *Cell*, 2018, 174(5): 1277-1292 e1214.
- 377 [27] Liu R, Hong J, Xu X, et al. Gut microbiome and serum metabolome alterations in obesity and
378 after weight-loss intervention [J]. *Nat Med*, 2017, 23(7): 859-868.
- 379 [28] Kondakova T, D'Heygere F, Feuilloley MJ, et al. Glycerophospholipid synthesis and functions in
380 *Pseudomonas* [J]. *Chem Phys Lipids*, 2015, 190(27-42).
- 381 [29] Fang W, Li C, Wu Q, et al. Metabolic profiling of chronic obstructive pulmonary disease model
382 rats and the interventional effects of HuaTanJiangQi decoction using UHPLC-Q-TOF/MS(E) [J].
383 *J Pharm Biomed Anal*, 2020, 180(113078).
- 384 [30] Loering S, Cameron GJM, Starkey MR, et al. Lung development and emerging roles for type 2
385 immunity [J]. *J Pathol*, 2019, 247(5): 686-696.

- 386 [31] Balany J and Bhandari V. Understanding the Impact of Infection, Inflammation, and Their
387 Persistence in the Pathogenesis of Bronchopulmonary Dysplasia [J]. *Front Med (Lausanne)*,
388 2015, 2(90).
- 389 [32] Wang X-H, Jia H-L, Deng L, et al. Astragalus polysaccharides mediated preventive effects on
390 bronchopulmonary dysplasia in rats [J]. *Pediatric Research*, 2014, 76(4): 347-354.
- 391

Table 1 Demographic and clinical characteristics of the included patients

	Severe BPD group (n=10)	moderate BPD group (n=5)	mild BPD group (n=10)	control group (n=5)	P value
Gestational Age (mean ± SD)	30.46±2.18	32.54±1.35	31.76±1.54	31.57±0.61	0.138
Birth weight (g) (mean ± SD)	1396.6±373.00	1530.0±363.67	1574±211.72	1640±139.10	0.421
1□min Apgar(mean ± SD)	5.44±3.05	5.00±4.06	5.4±2.71	7.00±2.24	0.720
5□min Apgar (median)	8(8-9)	8(7-9)	8.5(5-10)	9(8-9)	0.819
10□min Apgar (median)	9(8-9)	8(8-9)	9(8-10)	10(9-10)	0.148
Male Gender n (%)	5(50%)	4(80%)	4(40%)	1(20%)	0.274
Han population, n (%)	10(100%)	4(80%)	10(100%)	5(100%)	0.160
Cesarean delivery, n (%)	5(50%)	5(100%)	8(80%)	5(100%)	0.069
Antenatal steroids, n(%)	7(70%)	2(40%)	7(70%)	3(60%)	0.664
Rupture of membranes> 18 hours, n (%)	1(10%)	1(20%)	1(10%)	1(20%)	0.902
Intrauterine growth restriction, n (%)	1(10%)	1(20%)	0(0%)	0(0%)	0.444
Treatment with surfactant, n (%)	7(30%)	2(40%)	8(80%)	3(60%)	0.466
Mechanical Ventilation hours (median)	608	222	265	144	0.003
Oxygen days	6(0-36)	11(7-23)	14.5(12-20)	11(9-18)	0.720
Antibiotic days (median)	39	16	23	14	0.011
Pneumonia, n (%)	10(100%)	5(100%)	9(90%)	5(100%)	0.558
Pulmonary hemorrhage, n (%)	5(50%)	2(40%)	3(30%)	0(0%)	0.272
Late onset sepsis, n (%)	5(50%)	0(0%)	5(50%)	1(20%)	0.170
Necrotizing	0(0%)	0(0%)	1(10%)	0(0%)	0.558

enterocolitis \geq					
stage 2, n (%)					




Figure 1 Diversity and composition of the lower-airway microbiome

(a) Shannon index at birth (Day 1); (b) Shannon index on Day 7 after birth (a greater Shannon index is indicative of higher microbial diversity); (c) Principal coordinate analysis (PCoA) of microbial communities at birth (Day 1) (d) PCoA of microbial communities on Day 7 after birth (samples located close to each other have similar microbial compositions, samples at distant locations have distinct microbial compositions); (e-f) Relative abundance of bacterial phyla (birth [Day 1], e; 7 days after birth, f). (g-h) Relative abundance of bacterial genera (birth [Day 1], g; 7 days

after birth, h). (A, severe BPD [n=10]; B, moderate BPD [n=5]; C, mild BPD [n=10]; D, no BPD [n=5]).




Figure 2 Abundance of *Stenotrophomonas*

(a) The abundance of *Stenotrophomonas* at birth (Day 1), $P < 0.05$; (b) the abundance of *Stenotrophomonas* on Day 7 after birth, $P=0.064$. (A, severe BPD [n=10]; B, moderate BPD [n=5]; C, mild BPD [n=10]; D, no BPD [n=5]).




Figure 3: Metabolic profiles

(a-b) Principal Component Analysis (PCA) based on the metabolic profiles in sputum samples (birth [Day 1], a; 7 days after birth, b); (c-f) Hierarchical clustering heat maps showing patterns in molecular data across groups. The relative amounts of the 86 compounds were transformed into Z scores (birth [Day 1] ES-, c; ES+, d; 7 days after birth ES-, e; ES+, f). (A, severe BPD [n=10]; B, moderate BPD [n=5]; C, mild BPD [n=10]; D, no BPD [n=5]). ES+: positive ion mode, ES-: negative ion mode)




Figure 4: sn-Glycerol 3-phosphoethanolamine level at birth (Day 1)

*: $P < 0.05$.




Figure 5: Scatter plot of the association between abundance of *Stenotrophomonas* and sn-glycerol 3-phosphoethanolamine level $r=0.45$, $P<0.05$.